Revlimid
Scottish Medicines Consortium approves Revlimid for two groups of blood cancer patients
October 14, 2020Research and Development Revlimid, SMC
The Scottish Medicines Consortium (SMC) has accepted Revlimid (lenalidomide) for routine use on NHS Scotland for patients with multiple myeloma …
NICE opts to reject Celgene’s Revlimid for newly diagnosed multiple myeloma after an autologous stem cell transplant
September 11, 2020Medical Communications, Sales and Marketing Celgene, NICE, Revlimid
It has emerged that NICE has opted to reject Celgene’s Revlimid (lenalidomide) for the maintenance of newly diagnosed multiple myeloma …
NICE recommends Celgene’s Revlimid combo for follicular lymphoma
February 27, 2020Sales and Marketing Cancer, Celgene, NICE, Revlimid, follicular lymphoma, pharma
NICE has chosen to recommend Celgene’s Revlimid (lenalidomide) for use on the NHS, it has emerged, alongside Genentech’s Rituxan (rituximab), …
FDA first as agency expands label on Celgene’s Revlimid in previously treated follicular or marginal zone lymphoma
May 29, 2019Research and Development, Sales and Marketing Cancer, Celgene, FDA, Revlimid, lymphoma, pharma
Celgene has revealed that the FDA has expanded its authorised indications of Revlimid (lenalidomide) to include combination with a rituximab …
NICE recommends Celgene’s Revlimid in treatment-naive multiple myeloma
May 20, 2019Sales and Marketing Celgene, NICE, Revlimid, UK, multiple myeloma
Celgene’s Revlimid (lenalidomide) has been recommended by NICE for use on the NHS in England and Wales in combination with …
Celgene’s Revlimid combo meets Phase 3 goal in relapsed/refractory indolent lymphoma
July 24, 2018Manufacturing and Production, Research and Development Celgene, Revlimid, lymphoma, pharma
Celgene has lifted the curtain on new Phase 3 data for its combo of Revlimid (lenalidomide) plus rituximab (R2) in …
Celgene hikes price of Revlimid to mask poor Q3 results
October 27, 2017Medical Communications, Sales and Marketing Celgene, Revlimid, biotech, drugs, pharma, pharmaceutical
Celgene posted its Q3 results and investors did not react well – shares plunged 16% immediately, after the biotech cut …
Celgene agrees one of the largest settlements for false claims on record
July 26, 2017Research and Development, Sales and Marketing Celgene, Revlimid, biotech, drugs, pharma, pharmaceutical, thalomid
It has been announced that Celgene has agreed to settle a case after a whistle-blower launched a lawsuit against the …
Celgene’s Revlimid scores first-of-its-kind myeloma indication in EU
January 27, 2017Sales and Marketing Celgene, Revlimid, multiple myeloma
Celgene’s Revlimid (lenalidomide) has become the first licensed monotherapy treatment for newly diagnosed multiple myeloma in patients who have undergone …
NICE rejects Celegene’s Revlimid as second-line treatment
November 16, 2016Research and Development, Sales and Marketing Celegene, Revlimid
NICE has decided Celegene’s multiple myeloma growth engine Revlimid (lenalidomide) will not be offered to patients as a second line …
Celgene’s Revlimid fails to improve overall survival from lymphoma in Phase III trial
July 26, 2016Research and Development Celgene, Revlimid, lymphoma
Celgene has announced the publication of data from a Phase III trial investigating Revlimid (lenalidomide) in diffuse large B-cell lymphoma …
Celgene says its Revlimid gets European approval to treat rare non-Hodgkin’s lymphoma
July 15, 2016Medical Communications, Research and Development, Sales and Marketing Celgene, European Commission, Revlimid, drug approval, drug trial, oncology
Celgene (Nasdaq: CELG) said the European Commission (EC) has approved Revlimid (lenalidomide) to treat a rare form of non-Hodgkin’s lymphoma.
Two Celgene cancer drugs approved in Ireland
March 1, 2016Research and Development, Sales and Marketing Abraxane, Cancer, Celgene, Revlimid, imnovid
Irish regulators have recommended two cancer treatments from Celgene: Imnovid (pomalidomide), in combination with dexamethasone, for previously-treated relapsed and refractory …
Celgene settles Revlimid patent dispute
December 23, 2015Manufacturing and Production, Research and Development, Sales and Marketing Celgene, India, Natco, Revlimid, lenalidomide, patents
Celgene has settled its litigation with Natco Pharma, over the patents for Revlimid, opening the door to increased generic competition …
MSD’s Keytruda shows promise in multiple myeloma
December 7, 2015Manufacturing and Production MSD, Revlimid, dexamethasone, keytruda, multiple myeloma, pembrolizumab
MSD has announced that it has initiated two Phase III studies based in part on the strength of early data, …
